DATA Globaldata Plc

RNS Number:4931T
Provalis PLC
3 November 2000


             PROVALIS SIGNS OPTION AGREEMENT WITH
   PHARMACEUTICS INTERNATIONAL INC., RELATING TO CERTAIN OF
             PROVALIS' DRUG DELIVERY TECHNOLOGIES.

Provalis  today announces that it has entered into  an  Option
Agreement  with Pharmaceutics International Inc., (PII)  under
which  PII is granted an exclusive option to acquire Provalis'
HALO(TM) and Capricorn(TM) drug delivery technologies. Provalis 
has already  received  an  initial payment, and will receive a
further  undisclosed sum in the event that PII  exercises  its
option,  which  it  must do within 12 months,  or  the  option
lapses.

Commenting on this agreement, Phil Gould, CEO of Provalis plc,
commented  "We  are  very pleased to have  entered  into  this
agreement with PII which represents the latest stage in our on-
going  disposal of a number of our drug delivery technologies,
allowing  us  to  focus on the development of  our  infectious
disease vaccine portfolio".

Commenting  on this agreement, Steve King, Vice  President  of
Business Development of Pharmaceutics International,  Inc. (PII)
, said 'These  patents  supplement PII's  drug  delivery  
portfolio and provide  a  platform  for future growth of PII's 
drug delivery system services'.



Provalis' Internet Website ; http://www.provalis.com

'Safe  Harbor'  Statement  under  the  US  Private  Securities
Litigation  Reform Act of 1995:  Some or all of the statements
in  this  document that relate to future plans,  expectations,
events,   performances  and  the  like  are  forward   looking
statements  as defined in the US Private Securities Litigation
Reform  Act  of 1995.  Actual results of events  could  differ
materially  from  those  described  in  the  forward   looking
statements  due to a variety of factors, including  those  set
forth  in  Provalis plc's filings with the US  Securities  and
Exchange Commission.

For further information:-

Dr Phil Gould, Provalis plc,  Tel:  + 44 (0) 1244 833463
Mr Lee Greenbury, Provalis plc,  Tel: + 44 (0) 1244 833402
Lisa Baderoon, Buchanan Communications,  
Tel: + 44 (0) 20 7466 5000


Notes to Editors

Provalis  plc  (LSE.PRO  and  NASDAQ.PVLS)  is  an  integrated
healthcare  business with three separate divisions focused  on
the   supply   and   sale  of  prescription   medicines,   the
development,  manufacture  and  sale  of  medical  diagnostics
worldwide,  and  the development of new therapeutic  products,
such as vaccines to combat infectious diseases.
The three divisions are:-

Healthcare - This division sells and markets branded,  third
party,  prescription medicines in the UK to GPs and  hospitals
through its own regionally managed sales force.  This division
sells products in the areas of gastroenterology, osteoporosis,
migraine and dermatology.

Medical Diagnostics - This division develops and sells medical
diagnostic  products  to world markets  through  distributors.
The   division  has  an  established  business  in  diagnostic
products for infectious diseases and has recently launched the
innovative  products Glycosal(TM) and Osteosal(TM) in the  
areas of diabetes and osteoporosis respectively.

Therapeutic Research & Development - This division develops  a
range of vaccine candidates for infectious diseases through  a
network of research collaborators.



For further information on PII:

PII's Internet Website;        http://www.pharm-int.com

Steve King,   Telephone      (410) 584-0001
              Fax:           (410) 584-0007
              Email:        sjking@pharm-int.com


PII  is  a  privately  owned contract formulation  development
company  specializing  in solid and semi-solid  pharmaceutical
dosage  forms.   Based in Baltimore, USA  the  company  has  a
72,000  sq. ft cGMP manufacturing facility.  PII is a  service
company  committed  to  producing a quality  on  time  service
focused to customer needs.

Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024

Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024